Results 101 to 110 of about 124,971 (293)
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya +2 more
wiley +1 more source
To explore the hub comorbidity genes and potential pathogenic mechanisms of hypopharyngeal carcinoma with esophageal carcinoma, and evaluate their diagnostic value for hypopharyngeal carcinoma with co-morbid esophageal carcinoma.
Jianing Zhang +6 more
doaj +1 more source
Gastric tube ulcer perforating the pericardium after subtotal esophagectomy [Perforacija ulkusa želučanog supstituta u perikard nakon subtotalne ezofagektomije] [PDF]
Subtotal esophagectomy with retrosternal transposition of the gastric tube to the neck was performed in a 62-year-old patient with squamous cell carcinoma of the proximal third of the esophagus.
Korušić, Anđelko +5 more
core
Feeding enterostomy during MIE was evaluated in 19 054 patients from the Japanese NCD using propensity weighting. Enterostomy was associated with higher reoperation and respiratory complications, but lower delayed gastric emptying and deep vein thrombosis, with no significant difference in overall bowel obstruction.
Eisuke Booka +7 more
wiley +1 more source
Intratumoral heterogeneity of esophageal squamous cell carcinoma [PDF]
The advent of large scale genome characterization led to rapidly increasing knowledge of genetic landscapes of malignancies in recent years. Besides a difference in quantity of mutations between different entities, studies revealed as well a difference in the amount of mutations in varying locations of a single neoplastic lesion: the relation of ...
openaire +2 more sources
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki +9 more
wiley +1 more source
Esophageal carcinoma is an aggressive cancer with a poor therapeutic response and a significant risk of recurrence after radical resection. It usually metastasizes to the lung, bones, or liver.
Tivadar Bara +7 more
doaj +1 more source
This meta‐analysis of 208 cases shows that salvage esophagectomy for cT4 esophageal squamous cell carcinoma achieves a 72% R0 resection rate, offering a curative pathway for selected patients. However, it remains a high‐risk procedure with an 18% anastomotic leak rate and 30% major complications (Clavien–Dindo ≥ III).
Makoto Sakai +4 more
wiley +1 more source
Programmed cell death 6 interacting protein (PDCD6IP) and Rabenosyn-5 (ZFYVE20) are potential urinary biomarkers for upper gastrointestinal cancer [PDF]
PURPOSE: Cancer of the upper digestive tract (uGI) is a major contributor to cancer-related death worldwide. Due to a rise in occurrence, together with poor survival rates and a lack of diagnostic or prognostic clinical assays, there is a clear need ...
Adachi +68 more
core +1 more source
Abstract Pharyngeal high‐resolution manometry with impedance (P‐HRM‐I) is an established assessment method used to evaluate pharyngeal swallowing. It provides precise quantification of swallowing biomechanics that enable the detection of alterations in swallowing physiology.
Mistyka Schar +5 more
wiley +1 more source

